Adverse drug reactions to the three doses of the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) mRNA-1273 vaccine in a cohort of cancer patients under active treatment of a tertiary hospital in Madrid, Spain [version 2; peer review: 2 approved]

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines efficacy and safety have been tested in phase 3 studies in which cancer patients were not included or were underrepresented. Methods: The objective of this study is to evaluate the safety profile of the mRNA-1273 vacci...

Descripció completa

Dades bibliogràfiques

Autors principals:	Ignacio Martinez Capella, Sara Gil Useros, Macarena Torrego Ellacuría, Laura Llorente Sanz, Jorge Bartolomé Arcilla, Paloma Flores Navarro, Alicia de Luna Aguilar, Alberto Delgado-Iribarren García-Campero, Javier David Benitez Fuentes, Elvira Baos Muñoz, Alejandro Francisco Jimenez Ortega, Pedro Pérez Segura
Format:	Artigo
Idioma:	Inglês
Publicat:	F1000 Research Ltd 2022-07-01
Col·lecció:	F1000Research
Matèries:	COVID-19 mRNA-1273 Vaccine SARS-CoV-2 Safety Cancer Oncology eng
Accés en línia:	https://f1000research.com/articles/11-434/v2
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!